Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details Narrative)

v3.19.2
Significant Accounting Policies (Details Narrative)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
USD ($)
Breathalyzers
shares
Jun. 30, 2018
USD ($)
Breathalyzers
shares
Jun. 30, 2019
USD ($)
Breathalyzers
shares
Jun. 30, 2018
USD ($)
Breathalyzers
shares
Dec. 31, 2018
USD ($)
Breathalyzers
Restricted cash $ 115,094   $ 115,094   $ 500,000
Maturities of securities     less than one year    
Unrealized gain on securities 18,059   $ 47,402    
Unrealized loss on securities   $ (4,401)   $ 12,443  
Marketable securities, loss 543 4,400 (4,258)  
Proceeds from sale of marketable securities 502,126 2,004,580 1,354,646 2,306,675  
Allowances for doubtful accounts for trade receivables 605,848   605,848   606,835
Bad debt expenses 0 125,500 4,247 125,500  
Trade receivables 266,860   266,860   176,326
Depreciation expense 9,542 13,675 14,975 27,350  
Intangible assets, net 223,407   223,407   243,411
Amortization expense 10,002 42,777 20,004 85,553  
Accrued liabilities 1,000   1,000   23,179
Rebates recognized during period 7,679 16,377 $ 6,350 43,894  
Income tax examination, likelihood percentage     The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.    
Unrecognized tax benefits    
Income tax benefit  
Accrued for penalties and interest  
Product cost of sales 219,864 302,826 465,801 600,326  
Cost of net revenue 15,660 37,993 27,579 64,937  
Net loss attributable to common shareholders $ 794,891 $ 2,067,453 $ 1,711,849 $ 3,927,444  
Weighted average basic and diluted common shares outstanding | shares 12,500,923 11,656,788 12,492,115 10,293,569  
Shipping and Handling [Member]          
Product cost of sales $ 9,511 $ 18,739 $ 21,997 $ 13,641  
Patents, Trademarks and Customer Lists [Member]          
Intangible assets, net 3,897,635   3,897,635    
Intangible assets, accumulated amortization $ 3,674,228   $ 3,674,228    
Sales Revenue, Net [Member]          
Concentration risk percentage 81.00% 72.00% 78.00% 66.00%  
Concentration risk, number of customer | Breathalyzers 3   3 2  
Sales Revenue, Net [Member] | Customer One [Member]          
Concentration risk percentage 42.00% 33.00% 45.00% 49.00%  
Sales Revenue, Net [Member] | Customer Two [Member]          
Concentration risk percentage 20.00% 27.00% 44.00% 17.00%  
Sales Revenue, Net [Member] | Customer Three [Member]          
Concentration risk percentage 19.00% 12.00%      
Trade Receivable [Member]          
Concentration risk percentage     76.00%   73.00%
Concentration risk, number of customer | Breathalyzers     2   2
Trade Receivable [Member] | Customer One [Member]          
Concentration risk percentage     53.00%   59.00%
Trade receivables $ 458,902   $ 458,902   $ 458,902
Trade Receivable [Member] | Customer Two [Member]          
Concentration risk percentage     23.00%   14.00%
Trade receivables $ 201,330   $ 201,330   $ 111,037
Cost of Goods [Member]          
Concentration risk percentage 76.00% 24.00% 50.00%    
Concentration risk, number of supplier | Breathalyzers 2 2 1    
Cost of Goods [Member] | Supplier Two [Member]          
Concentration risk percentage 66.00% 11.00%      
Cost of Goods [Member] | Supplier One [Member]          
Concentration risk percentage 0.00% 13.00%      
Trade Payables [Member] | Three Vendors [Member]          
Concentration risk percentage     70.00%    
Concentration risk, number of supplier | Breathalyzers     2    
Trade Payables [Member] | Vendor One [Member]          
Trade receivables $ 180,114   $ 180,114    
Trade Payables [Member] | Vendor Two [Member]          
Trade receivables 123,000   123,000    
Trade Payables [Member] | Vendor Three [Member]          
Trade receivables $ 116,206   $ 116,206    
Minimum [Member]          
Normal credit terms extended to customers     30 days    
Minimum [Member] | Cost of Goods [Member] | One Supplier [Member]          
Concentration risk percentage        
Concentration risk, number of supplier | Breathalyzers        
Maximum [Member]          
Normal credit terms extended to customers     90 days